FDA
- Status: approved
HX575 recombinant human erythropoietin alfa (HX575 recombinant human erythropoietin alfa) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Sandoz is the originator. The local marketing authorisation holder may differ — check the official source linked above.